Monitor for actual sales under this ATM program, as the $6.36 million represents a ceiling rather than a guaranteed amount. The capital will support PH-762 development but introduces dilution risk. Check future 10-Q filings for disclosure of shares sold and net proceeds received.
Price Chart
Executive Summary
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock. This capital raise follows a recent shelf registration and is intended to fund development of PH-762 and general working capital. The offering introduces potential near-term dilution.
Key Financial Metrics
Key Facts
- Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock
- The offering is being conducted pursuant to a shelf registration statement declared effective on July 1, 2024
- Proceeds will be used to advance PH-762 into a Phase 2b/3 trial and for general working capital
- H.C. Wainwright will receive a 3.0% commission on gross proceeds from sales
- The company has no obligation to sell any shares and may suspend or terminate the offering at any time
Financial Impact
Up to $6.36 million in potential proceeds, with 3.0% commission paid to the placement agent
Risk Factors
- Dilution to existing shareholders if the full $6.36 million is raised
- Potential downward pressure on stock price from incremental share issuance
- No assurance that any shares will be sold under the agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-011761 |
| Exhibit: ex_942764.htm | 0001437749-26-011761 |
| Document: phio20260402_8k.htm | 0001437749-26-011761 |
| Document: 0001437749-26-011761-index-headers.html | 0001437749-26-011761 |
| Document: 0001437749-26-011761-index.html | 0001437749-26-011761 |
| Document: 0001437749-26-011761.txt | 0001437749-26-011761 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $1.03 $1.01 | ▼ −1.94% | ▼ −2.05% | $1.00 (−2.91%) |
Aug 14, 2026 6w ago | DEFA14A | $1.06 $1.17 | ▲ +10.38% | ▲ +11.57% | $1.00 (−5.66%) |
Apr 8, 2026 25w ago | 8-K | $1.25 $1.27 | ▲ +1.60% | ▼ −1.59% | $1.00 (−20.00%) |
Apr 8, 2026 25w ago | 424B5 | $1.25 $1.27 | ▲ +1.60% | ▼ −1.59% | $1.00 (−20.00%) |
Mar 5, 2026 30w ago | 8-K | $1.16 $1.17 | ▲ +0.86% | ▲ +2.39% | $1.00 (−13.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access